Citadel Advisors
TBPH icon

Citadel Advisors’s Theravance Biopharma TBPH Stock Holding History

Citadel Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$524K Buy
30,800
+18,600
+152% +$308K ﹤0.01% 9753
2026
Q1 		$198K Buy
+12,200
New +$216K ﹤0.01% 11431
2025
Q2 		– Sell
-1,400
Closed -$12.5K – 15036
2025
Q1 		$12.5K Buy
1,400
+1,100
+367% +$10.2K ﹤0.01% 13444
2024
Q4 		$2.82K Sell
300
-900
-75% -$8.19K ﹤0.01% 14049
2024
Q3 		$9.67K Sell
1,200
-1,900
-61% -$16.5K ﹤0.01% 13243
2024
Q2 		$26.3K Buy
3,100
+800
+35% +$7.22K ﹤0.01% 12396
2024
Q1 		$20.6K Buy
2,300
+2,200
+2,200% +$20.4K ﹤0.01% 12997
2023
Q4 		$1.12K Buy
+100
New +$1.01K ﹤0.01% 13872
2023
Q3 		– Sell
-5,000
Closed -$51.8K – 15095
2023
Q2 		$51.8K Sell
5,000
-24,500
-83% -$271K ﹤0.01% 11758
2023
Q1 		$320K Sell
29,500
-3,700
-11% -$39.1K ﹤0.01% 9253
2022
Q4 		$373K Buy
+33,200
New +$349K ﹤0.01% 8859
2021
Q4 		– Sell
-21,400
Closed -$158K – 14740
2021
Q3 		$158K Buy
+21,400
New +$239K ﹤0.01% 12312
2019
Q3 		– Sell
-12,000
Closed -$196K – 9744
2019
Q2 		$196K Buy
+12,000
New +$243K ﹤0.01% 8205
2016
Q1 		– Sell
-100
Closed -$2K – 7918
2015
Q4 		$2K Buy
+100
New +$1.59K ﹤0.01% 8584
2015
Q3 		– Sell
-6,700
Closed -$87K – 9226
2015
Q2 		$87K Buy
6,700
+5,100
+319% +$79.1K ﹤0.01% 7223
2015
Q1 		$28K Sell
1,600
-1,800
-53% -$33K ﹤0.01% 7726
2014
Q4 		$51K Sell
3,400
-6,500
-66% -$113K ﹤0.01% 7182
2014
Q3 		$228K Buy
9,900
+6,900
+230% +$200K ﹤0.01% 5593
2014
Q2 		$96K Buy
+3,000
New +$90.3K ﹤0.01% 6260

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Citadel Advisors's TBPH Position: Q2 2026 in Review

Citadel Advisors increased its Theravance Biopharma (TBPH) stake by 489% in Q2 2026, buying an estimated $6.96M and bringing the position to 506,668 shares worth $8.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3803.

Citadel Advisors first reported a position in TBPH in Q2 2014 and has held it in 34 quarters since. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Citadel Advisors held 506,668 shares of Theravance Biopharma worth $8.61M as of Q2 2026.
  • Citadel Advisors bought 420,577 Theravance Biopharma shares in Q2 2026, an estimated $6.96M.
  • Theravance Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3803 holding.
  • Citadel Advisors first reported a position in Theravance Biopharma in Q2 2014 and has held it in 34 quarters since.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.